371 related articles for article (PubMed ID: 23954893)
21. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
[TBL] [Abstract][Full Text] [Related]
22. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
[TBL] [Abstract][Full Text] [Related]
23. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
24. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
25. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
[TBL] [Abstract][Full Text] [Related]
26. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
[TBL] [Abstract][Full Text] [Related]
27. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).
Steinhäuser S; Silva P; Lenk L; Beder T; Hartmann A; Hänzelmann S; Fransecky L; Neumann M; Bastian L; Lipinski S; Richter K; Bultmann M; Hübner E; Xia S; Röllig C; Vogiatzi F; Schewe DM; Yumiceba V; Schultz K; Spielmann M; Baldus CD
Leukemia; 2023 Jan; 37(1):134-142. PubMed ID: 36411356
[TBL] [Abstract][Full Text] [Related]
28. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A; Menendez JA
Carcinogenesis; 2019 Mar; 40(1):27-40. PubMed ID: 30428017
[TBL] [Abstract][Full Text] [Related]
29. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.
Kattih B; Shirvani A; Klement P; Garrido AM; Gabdoulline R; Liebich A; Brandes M; Chaturvedi A; Seeger T; Thol F; Göhring G; Schlegelberger B; Geffers R; John D; Bavendiek U; Bauersachs J; Ganser A; Heineke J; Heuser M
Leukemia; 2021 May; 35(5):1301-1316. PubMed ID: 32948843
[TBL] [Abstract][Full Text] [Related]
30. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Issa GC; DiNardo CD
Blood Cancer J; 2021 Jun; 11(6):107. PubMed ID: 34083508
[TBL] [Abstract][Full Text] [Related]
32. Plk1 regulates mutant IDH1 enzyme activity and mutant IDH2 ubiquitination in mitosis.
Saikiran Reddy M; Bhattacharjee D; Jain N
Cell Signal; 2022 Apr; 92():110279. PubMed ID: 35143931
[TBL] [Abstract][Full Text] [Related]
33. Genetic Polymorphism Study of IDH 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
[TBL] [Abstract][Full Text] [Related]
34. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
DiNardo CD; Propert KJ; Loren AW; Paietta E; Sun Z; Levine RL; Straley KS; Yen K; Patel JP; Agresta S; Abdel-Wahab O; Perl AE; Litzow MR; Rowe JM; Lazarus HM; Fernandez HF; Margolis DJ; Tallman MS; Luger SM; Carroll M
Blood; 2013 Jun; 121(24):4917-24. PubMed ID: 23641016
[TBL] [Abstract][Full Text] [Related]
35.
Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
[TBL] [Abstract][Full Text] [Related]
36. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
[TBL] [Abstract][Full Text] [Related]
37. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
[TBL] [Abstract][Full Text] [Related]
38. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.
Fathi AT; Wander SA; Faramand R; Emadi A
Semin Hematol; 2015 Jul; 52(3):165-71. PubMed ID: 26111463
[TBL] [Abstract][Full Text] [Related]
39. IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
Libura M; Bialopiotrowicz E; Giebel S; Wierzbowska A; Roboz GJ; Piatkowska-Jakubas B; Pawelczyk M; Gorniak P; Borg K; Wojtas M; Florek I; Matiakowska K; Jazwiec B; Solarska I; Noyszewska-Kania M; Piechna K; Zawada M; Czekalska S; Salamanczuk Z; Karabin K; Wasilewska K; Paluszewska M; Urbanowska E; Gajkowska-Kulik J; Semenczuk G; Rybka J; Wrobel T; Ejduk A; Kata D; Grosicki S; Robak T; Pluta A; Kominek A; Piwocka K; Pyziak K; Sroka-Porada A; Wrobel A; Przybylowicz A; Wojtaszewska M; Lewandowski K; Gil L; Piekarska A; Knopinska W; Bolkun L; Warzocha K; Kuliczkowski K; Sacha T; Basak G; Jedrzejczak WW; Holowiecki J; Juszczynski P; Haus O
Sci Rep; 2021 May; 11(1):10017. PubMed ID: 33976256
[TBL] [Abstract][Full Text] [Related]
40. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]